Wall Street Zen downgraded shares of Climb Bio (NASDAQ:CLYM – Free Report) from a hold rating to a sell rating in a report published on Sunday,Wall Street Zen reports.
Other equities research analysts also recently issued reports about the company. Oppenheimer upped their target price on Climb Bio from $18.00 to $25.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 8th. Guggenheim reiterated a “buy” rating on shares of Climb Bio in a research report on Monday, October 26th. Royal Bank Of Canada initiated coverage on Climb Bio in a research note on Monday, August 3rd. They issued an “outperform” rating and a $23.00 price objective on the stock. BTIG Research restated a “buy” rating and issued a $32.00 price objective on shares of Climb Bio in a report on Tuesday, October 27th. Finally, Raymond James Financial restated a “strong-buy” rating on shares of Climb Bio in a report on Thursday, November 5th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $28.14.
View Our Latest Report on CLYM
Climb Bio Trading Down 1.6%
Shares of NASDAQ:CLYM opened at $9.78 on Friday. The company has a 50 day moving average of $11.34 and a 200-day moving average of $10.68. The firm has a market cap of $574.48 million, a P/E ratio of -11.93 and a beta of 0.01. Climb Bio has a twelve month low of $1.63 and a twelve month high of $18.33.
Climb Bio (NASDAQ:CLYM – Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.02. Equities research analysts forecast that Climb Bio will post -0.75 EPS for the current year.
Insider Activity
In other news, Director Stephen Thomas sold 100,000 shares of the company’s stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $13.67, for a total transaction of $1,367,000.00. Following the completion of the sale, the director directly owned 467,969 shares of the company’s stock, valued at $6,397,136.23. This represents a 17.61% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 2.60% of the stock is owned by company insiders.
Hedge Funds Weigh In On Climb Bio
Institutional investors have recently bought and sold shares of the stock. Dimensional Fund Advisors LP acquired a new stake in shares of Climb Bio during the first quarter valued at approximately $715,000. BlackRock Inc. purchased a new stake in shares of Climb Bio in the 2nd quarter valued at approximately $30,708,000. Braidwell LP lifted its position in shares of Climb Bio by 102.6% in the 2nd quarter. Braidwell LP now owns 3,099,027 shares of the company’s stock valued at $40,411,000 after acquiring an additional 1,569,352 shares in the last quarter. Bank of New York Mellon Corp purchased a new stake in shares of Climb Bio in the 2nd quarter valued at approximately $1,613,000. Finally, The Manufacturers Life Insurance Company acquired a new position in Climb Bio in the 2nd quarter worth approximately $2,148,000. Hedge funds and other institutional investors own 69.76% of the company’s stock.
About Climb Bio
Climb Bio is a clinical-stage biopharmaceutical company developing treatments for autoimmune and inflammatory diseases, with a focus on conditions involving B cells and antibody production. Its lead candidate, budoprutug, is an antibody designed to engage CD19 and FcγRIIb to inhibit B-cell activity. The company is evaluating the candidate in clinical studies for immune-mediated diseases, including immune thrombocytopenia and membranous nephropathy. Climb Bio is also developing CLYM-116, an antibody targeting APRIL, a protein involved in B-cell and antibody activity.
Featured Articles
- Five stocks we like better than Climb Bio
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Climb Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Climb Bio and related companies with MarketBeat.com's FREE daily email newsletter.
